Alkermes reports early ADHD success for orexin agonist, signaling potential blockbuster

Key points

• Alkermes reported that ALKS 7290, an orexin agonist, reduced ADHD symptoms in a Phase 1b trial of 50 adults, with score improvements of 14 and 19 points on the Adult ADHD Investigator Symptom Rating Scale for 20mg and 50mg doses respectively.
• The company is moving quickly to Phase 2 trials, which will test three dosing paradigms over four weeks, and plans subsequent trials in children, citing the rising diagnosis rates of ADHD in younger populations.
• CEO Blair Jackson described the drug as a potential 'company changer,' particularly when combined with alixorexton, another orexin agonist in development for narcolepsy and hypersomnia.
• Needham reiterated a 'Buy' rating with a $62 price target, while GuruFocus notes the stock is trading at $43.93, which is 34.8% above its intrinsic value, and insider selling has been significant.
• Common side effects reported in the trial included dizziness, constipation, and increased urinary frequency, with no new safety signals identified.

Background

This development follows the FDA approval of Takeda's Orzeyful in August 2026, the first orexin agonist for narcolepsy, which validated the potential of this drug class. Alkermes is positioning its pipeline to expand beyond sleep disorders into broader neuropsychiatric conditions, similar to how GLP-1 drugs expanded from diabetes to obesity. The company's current commercial portfolio includes Aristada and Lumryz, but lacks a blockbuster product, making the success of orexin agonists critical for future growth.

How outlets are covering it

Fierce Biotech and STAT both highlight the efficacy signals of ALKS 7290 in ADHD, with Fierce emphasizing the CEO's optimism about the drug's potential and STAT focusing on the specific symptom reduction data. GuruFocus provides a contrasting financial perspective, noting that while analysts like Needham maintain a 'Buy' rating, the stock is considered overvalued based on intrinsic value metrics and insider selling activity. This divergence suggests that while the scientific potential is promising, the market valuation may not fully reflect the current financial risks or intrinsic value.

Why it matters

The expansion of orexin agonists into ADHD could address a massive unmet need, as ADHD diagnosis rates are rising in both children and adults. If successful, ALKS 7290 could become a blockbuster for Alkermes, transforming its financial profile and establishing the orexin pathway as a viable treatment for conditions beyond sleep disorders. This could also influence the development of other CNS therapies and potentially shift the market dynamics for existing ADHD treatments like centanafadine.

What to watch

Alkermes is currently enrolling a Phase 2 trial for ALKS 7290, which will test three dosing paradigms over a four-week period. Following the accrual of further safety data in adults, the company plans to initiate trials in children. The market will be watching for the results of these Phase 2 trials to determine if the early efficacy signals translate into statistically significant outcomes, which could impact the stock's valuation and the company's future growth trajectory.